Neuphoria Therapeutics (NASDAQ:NEUP) shares gained 4% on Tuesday after the clinical-stage biotechnology firm announced the initiation of a strategic review aimed at maximizing shareholder value.

The company, which specializes in developing therapies for neuropsychiatric disorders, said it is evaluating a range of potential options — including mergers, acquisitions, partnerships, joint ventures, and licensing agreements. To support the process, Neuphoria has retained H.C. Wainwright & Co. as its exclusive financial advisor.

As part of the announcement, Neuphoria revealed that it received an unsolicited, non-binding indication of interest on November 10, 2025, from Lynx1 Master Fund LP, which expressed a desire to acquire all outstanding shares it does not currently own for $5.20 per share in cash. Lynx1 also stated its intention to nominate candidates for Neuphoria’s Board of Directors at the upcoming 2025 Annual Meeting of Stockholders, scheduled for December 12, 2025.

Neuphoria’s Board of Directors confirmed that it will review the Lynx1 proposal as part of its broader strategic process. The company emphasized, however, that no definitive timeline has been set and there is no assurance that any transaction will ultimately be completed or announced.

Neuphoria also advised shareholders not to take any action at this time, adding that any votes previously submitted under the October 30, 2025 proxy statement will be disregarded pending the outcome of the review.

Neuphoria Therapeutics stock price

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Some portions of this content may have been generated or assisted by artificial intelligence (AI) tools and been reviewed for accuracy and quality by our editorial team.